After colocalization and SMR analysis, 6 plasma proteins (FCRL3, SUGP1, TNFAIP3, EHBP1, HAPLN4, and CILP2) have been passed all tests and identified as having potential as therapeutic targets for RA. The gene discussed is CILP2; the disease is rheumatoid arthritis.